Natera Inc

Natera is a cell-free DNA technology company with Signatera (personalized cancer monitoring) and Panorama (prenatal testing) as its commercial anchors. Its 17 trials include 2 Phase 2 and 6 Phase 3 studies focused on validating ctDNA-guided therapy decisions in multiple cancer types. Insider buying at 1,150 transactions is a very strong signal for a commercial-stage diagnostics company. Natera's Signatera oncology monitoring reimbursement expansion is the most important near-term catalyst.

<article class="bts-verified-summary" data-ticker="NTRA">
<p>Natera Inc (NTRA) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>NTRA has 7 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Natera+Inc%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001604821 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22NTRA%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>